Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Prolonged activity of factor IX as a monomeric Fc fusion protein.

Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, Zarbis-Papastoitsis G, Reidy TJ, Merricks EP, Nichols TC, Bitonti AJ.

Blood. 2010 Mar 11;115(10):2057-64. doi: 10.1182/blood-2009-08-239665. Epub 2010 Jan 7.

2.

Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.

Toby GG, Liu T, Buyue Y, Zhang X, Bitonti AJ, Pierce GF, Sommer JM, Jiang H, Peters RT.

PLoS One. 2016 Feb 3;11(2):e0148255. doi: 10.1371/journal.pone.0148255. eCollection 2016.

3.

Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.

Nolte MW, Nichols TC, Mueller-Cohrs J, Merricks EP, Pragst I, Zollner S, Dickneite G.

J Thromb Haemost. 2012 Aug;10(8):1591-9. doi: 10.1111/j.1538-7836.2012.04826.x.

4.

Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.

Iorio A, Krishnan S, Myrén KJ, Lethagen S, McCormick N, Yermakov S, Karner P.

J Med Econ. 2017 Apr;20(4):337-344. doi: 10.1080/13696998.2016.1265973. Epub 2016 Dec 21.

PMID:
27885871
5.

Chimeric proteins comprising the constant region of immunoglobulins for treating hemophilia B (WO2005001025).

Taupin P.

Expert Opin Ther Pat. 2011 Jun;21(6):967-70. doi: 10.1517/13543776.2011.577070. Epub 2011 Apr 9.

PMID:
21476878
6.

Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.

Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Leppanen SD, Rup BJ, Keith JC Jr, Garzone PD, Schaub RG.

Blood. 1996 Oct 1;88(7):2603-10.

7.

Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.

Powell JS, Apte S, Chambost H, Hermans C, Jackson S, Josephson NC, Mahlangu JN, Ozelo MC, Peerlinck K, Pasi J, Perry D, Ragni MV, Wang X, Jiang H, Li S, Cristiano LM, Innes A, Nugent K, Brennan A, Luk A, Allen G, Pierce GF, Robinson B.

Br J Haematol. 2015 Jan;168(1):124-34. doi: 10.1111/bjh.13112. Epub 2014 Sep 11.

PMID:
25208598
8.

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

Shapiro AD, Ragni MV, Valentino LA, Key NS, Josephson NC, Powell JS, Cheng G, Thompson AR, Goyal J, Tubridy KL, Peters RT, Dumont JA, Euwart D, Li L, Hallén B, Gozzi P, Bitonti AJ, Jiang H, Luk A, Pierce GF.

Blood. 2012 Jan 19;119(3):666-72. doi: 10.1182/blood-2011-07-367003. Epub 2011 Nov 22.

9.

Evaluation of the toxicology, pharmacokinetics, and local tolerance of recombinant factor IX Fc fusion protein in animals.

Dumont JA, Loveday KS, Light DR, Pierce GF, Jiang H.

Thromb Res. 2015 Aug;136(2):371-8. doi: 10.1016/j.thromres.2015.01.020. Epub 2015 Jan 23.

10.

Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.

Fischer K, Kulkarni R, Nolan B, Mahlangu J, Rangarajan S, Gambino G, Diao L, Ramirez-Santiago A, Pierce GF, Allen G.

Lancet Haematol. 2017 Feb;4(2):e75-e82. doi: 10.1016/S2352-3026(16)30193-4.

PMID:
28159192
11.

Eftrenonacog Alfa: A Review in Haemophilia B.

Hoy SM.

Drugs. 2017 Jul;77(11):1235-1246. doi: 10.1007/s40265-017-0778-1.

PMID:
28646426
12.

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D, Manco-Johnson MJ, Apte S, Baker RI, Chan GC, Novitzky N, Wong RS, Krassova S, Allen G, Jiang H, Innes A, Li S, Cristiano LM, Goyal J, Sommer JM, Dumont JA, Nugent K, Vigliani G, Brennan A, Luk A, Pierce GF; B-LONG Investigators.

N Engl J Med. 2013 Dec 12;369(24):2313-23. doi: 10.1056/NEJMoa1305074. Epub 2013 Dec 4.

13.

Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.

Powell J, Shapiro A, Ragni M, Negrier C, Windyga J, Ozelo M, Pasi J, Baker R, Potts J, Li S, Mei B, Pierce GF, Robinson B.

Br J Haematol. 2015 Jan;168(1):113-23. doi: 10.1111/bjh.13109. Epub 2014 Sep 11.

PMID:
25209873
14.

Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity.

Sommer JM, Buyue Y, Bardan S, Peters RT, Jiang H, Kamphaus GD, Gray E, Pierce GF.

Thromb Haemost. 2014 Nov;112(5):932-40. doi: 10.1160/TH13-11-0971. Epub 2014 Aug 21.

15.

Half-life extension through albumin fusion technologies.

Schulte S.

Thromb Res. 2009 Dec;124 Suppl 2:S6-8. doi: 10.1016/S0049-3848(09)70157-4.

PMID:
20109653
16.

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias.

Mancuso ME, Mannucci PM.

Drug Des Devel Ther. 2014 Mar 28;8:365-71. doi: 10.2147/DDDT.S47312. eCollection 2014. Review.

17.

Recombinant FIXFc: a novel therapy for the royal disease?

Valentino LA.

Expert Opin Biol Ther. 2011 Oct;11(10):1361-8. doi: 10.1517/14712598.2011.603304. Epub 2011 Jul 22. Review.

PMID:
21780945
18.

Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.

Ducore JM, Miguelino MG, Powell JS.

Expert Rev Hematol. 2014 Oct;7(5):559-71. doi: 10.1586/17474086.2014.951322. Epub 2014 Aug 21.

PMID:
25142322
19.

Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.

Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S.

Thromb Haemost. 2009 Oct;102(4):634-44. doi: 10.1160/TH09-04-0255.

PMID:
19806248
20.

Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.

Perot E, Enjolras N, Le Quellec S, Indalecio A, Girard J, Negrier C, Dargaud Y.

Thromb Res. 2015 May;135(5):1017-24. doi: 10.1016/j.thromres.2015.02.034. Epub 2015 Mar 10.

PMID:
25795563

Supplemental Content

Support Center